April 12, 2022 -- NiKang Therapeutics presented preclinical data for NKT2152, a small molecule that inhibits hypoxia-inducible factor 2α (HIF2α), at the American Association for Cancer Research (AACR) Annual Meeting 2022.
Nikang's presentation highlighted NKT2152's mechanism of action, in vivo pharmacokinetic and pharmacodynamic profiles, and antitumor effect in multiple xenograft models, including clear cell renal cell carcinoma (ccRCC) and hepatocellular carcinoma.The NKT2152 preclinical data presented at AACR supports the advancement of the molecule into clinical studies, said Zhenhai Gao, PhD, president and CEO of NiKang. Furthermore, the preclinical data suggest that NKT2152 has potential for the treatment of other solid tumors.
NKT2152 is currently being evaluated in phases I and II of a clinical trial in patients with advanced ccRCC to determine its dosage, safety, efficacy, and pharmokinetics. Combination studies will follow once the recommended doses of NKT2152 are identified through this study.
Copyright © 2022 scienceboard.net